Top

Published in:

01-09-2009 | Epidemiology

Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence

Authors: Rinat Yerushalmi, Hagen Kennecke, Ryan Woods, Ivo A. Olivotto, Caroline Speers, Karen A. Gelmon

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Abstract

Purpose we evaluated whether patients with multifocal/multicentric (M/M) breast cancer have different outcomes compared to unifocal (U) disease in terms of survival and the development of contralateral breast cancer (CBC) disease. Methods women diagnosed with stage I–III breast cancer were classified as having U or M/M disease. Prognostic factors were prospectively collected and obtained from the breast cancer outcome unit database. Univariate and multivariable analyses for the incidence of CBC were performed as well as Kaplan–Meier plots. Results 25,320 women met inclusion criteria. The 5-year cumulative incidence of CBC in the U versus M/M group was 2.3% (95% CI 2.1, 2.5) versus 2.4% (95% CI 1.6, 3.4) (P = 0.349). Breast cancer specific survival (BCSS) rate revealed a slightly worse outcome with M/M disease, RR = 1.174 (95% CI 1,004, 1.372). Conclusions M/M breast cancer did not increase the risk of metachronous CBC, but was associated with inferior BCSS.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687–1717CrossRef

Fracchia AA, Borgen PI (1991) Bilateral breast cancer. Semin Surg Oncol 7:300–305. doi:10.1002/ssu.2980070513 PubMedCrossRef

Newman LA, Sahin AA, Cunningham JE (2001) Case-control study of unilateral and bilateral breast carcinoma patients. Cancer 91:1845–1853. doi:10.1002/1097-0142(20010515)91:10<1845::AID-CNCR1205>3.0.CO;2-ZPubMedCrossRef

Dawson PJ (1996) Bilateral and multifocal breast cancer. Cancer Control 3:258–266PubMed

Olivotto IA, Mates D, Kan L et al (1999) Prognosis, treatment, and recurrence of breast cancer for women attending or not attending the screening mammography program of British Columbia. Breast Cancer Res Treat 54:73–81. doi:10.1023/A:1006152918283 PubMedCrossRef

Scrucca L, Santucci A, Aversa F (1999) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40:381–387. doi:10.1038/sj.bmt.1705727 CrossRef

Satagopan JM, Ben-Porat L, Berwick M (2004) A note on competing risks in survival data analysis. Br J Cancer 91:1229–1235. doi:10.1038/sj.bjc.6602102 PubMedCrossRef

Robson ME, Chappuis PO, Satagopan J (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17. doi:10.1186/bcr658 PubMedCrossRef

Kim HT (2007) Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 13:559–565. doi:10.1158/1078-0432.CCR-06-1210 PubMedCrossRef

10.

Gray RJ (1988) Class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154. doi:10.1214/aos/1176350951 CrossRef

11.

Fine JP, Gray RJ (1999) Proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509. doi:10.2307/2670170 CrossRef

12.

Bertelsen L, Bernstein L, Olsen JH et al (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women’s environment, cancer and radiation epidemiology study. J Natl Cancer Inst 100:32–40. doi:10.1093/jnci/djm267 PubMed

13.

Coombs NJ, Boyages J (2005) Multifocal and multicentric breast cancer: does each focus matter? J Clin Oncol 23:7497–7502. doi:10.1200/JCO.2005.02.1147 PubMedCrossRef

14.

Schaapveld M, Visser O, Louwman WJ (2007) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197. doi:10.1007/s10549-007-9709-2

15.

Kuo WH, Yen AM, Lee PH (2006) Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan. Breast Cancer Res Treat 99:221–228. doi:10.1007/s10549-006-9194-z PubMedCrossRef

16.

Fowble B, Hanlon A, Freedman G et al (2001) Second cancers after conservative surgery and radiation for stages I–II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys 51:679–690. doi:10.1016/S0360-3016(01)01665-0 PubMed

17.

Gajalakshmi CK, Shanta V, Hakama M (1998) Risk factors for contralateral breast cancer in Chennai (Madras), India. Int J Epidemiol 27:743–750. doi:10.1093/ije/27.5.743 PubMedCrossRef

18.

Broet P, de la Rochefordiere A, Scholl SM (1995) Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 13:1578–1583PubMed

19.

Bernstein JL, Thompson WD, Risch N et al (1992) Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 136:925–936PubMed

20.

Kollias J, Ellis IO, Elston CW et al (2001) Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg 25:1117–1124PubMed

21.

Fechner RE (1972) Infiltrating lobular carcinoma without lobular carcinoma in situ. Cancer 29:1539–1545PubMedCrossRef

22.

du Toit RS, Locker AP, Ellis IO et al (1989) Invasive lobular carcinomas of the breast—the prognosis of histopathological subtypes. Br J Cancer 60:605–609PubMed

23.

DiCostanzo D, Rosen PP, Gareen I et al (1990) Prognosis in infiltrating lobular carcinoma. An analysis of “classical” and variant tumors. Am J Surg Pathol 14:12–23. doi:10.1097/00000478-199001000-00002 PubMedCrossRef

24.

Ji J, Hemminki K (2007) Risk for contralateral breast cancers in a population covered by mammography: effects of family history, age at diagnosis and histology. Breast Cancer Res Treat 105:229–236. doi:10.1007/s10549-006-9445-z PubMedCrossRef

25.

Chen AM, Meric-Bernstam F, Hunt KK et al (2005) Breast conservation after neoadjuvant chemotherapy. Cancer 103:689–695. doi:10.1002/cncr.20815 PubMedCrossRef

26.

Chua B, Ung O, Taylor R et al (2001) Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg 71:723–728. doi:10.1046/j.1445-1433.2001.02266.x PubMedCrossRef

27.

Andea AA, Bouwman D, Wallis T et al (2004) Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer 100:20–27. doi:10.1002/cncr.11880 PubMedCrossRef

28.

Andea AA, Wallis T, Newman LA et al (2002) Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer 94:1383–1390PubMedCrossRef

29.

Litton JK, Eralp Y, Gonzalez-Angulo AM et al (2007) Multifocal breast cancer in women ≤35 years old. Cancer 110:1445–1450. doi:10.1002/cncr.22928 PubMedCrossRef

Title: Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence
Authors: Rinat Yerushalmi
Hagen Kennecke
Ryan Woods
Ivo A. Olivotto
Caroline Speers
Karen A. Gelmon
Publication date: 01-09-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0265-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Novel and common BRCA1 mutations in familial breast/ovarian cancer patients from Lithuania

No evidence that GATA3 rs570613 SNP modifies breast cancer risk

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century

The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model

Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells

Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables

Keynote webinar | Spotlight on antibody–drug conjugates in cancer